European Journal of Pharmacology, 209 (1991) 287–289
© 1991 Elsevier Science Publishers B.V. All rights reserved 0014-2999/91/$03.50

Author index

Andersson, S.E. and Le Greves, P.
Ruthenium red and capsaicin induce a neurogenic inflammatory response in the rabbit eye: effects of ω-conotoxin GVIA and tetrodotoxin (209) 175
Angelucci, F., see Negri, L. (209) 163
Arlinghaus, L., Mehdi, S. and Lee, K.S.
Improved posthypoxic recovery with a membrane-permeable calpain inhibitor (209) 123
Asano, T., see Sako, K. (209) 39
Ashby, Jr., C.R., see Minabe, Y. (209) 143
Ashby, Jr., C.R., see Minabe, Y. (209) 151

Barrigón, S., see Salinas, P. (209) 105
Barthelemy, C., see Zongazo, M.A. (209) 45
Batchelor, A.M., see East, S.J. (209) 119
Benishin, C., see Hu, P.-S. (209) 87
Bluthé, R.-M., Dantzer, R. and Kelley, K.W.
Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor α in mice (209) 281
Bobillier, P., see Lepetit, P. (209) 207
Bousquet, P., see Tibiriça, E. (209) 213
Brus, R., see Kostrzewa, R.M. (209) 157

Cai, N.-s., see Kiss, B. (209) 109
Calenco-Choukroun, G., Daugé, V., Gacel, G. and Roques, B.P.
Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a μ-opioid receptor agonist (209) 267
Campbell, B.J., Dimaline, R., Dockray, G.J. and Hughes, J.
Inhibition of food intake by omeprazole in the chicken (209) 231
Carayon, A., see Zongazo, M.A. (209) 45
Chiba, S., see Iwatsuki, K. (209) 63
Czachura, J.F., see Rasmussen, K. (209) 135

Dantzer, R., see Bluthé, R.-M. (209) 281
Darrow, E., Strahlendorf, J.C. and Strahlendorf, H.K.
Extracellular magnesium concentration alters Purkinje cell responsiveness to serotonin and analogues (209) 19
Daugé, V., see Calenco-Choukroun, G. (209) 267
De Simoni, M.G., see Gemma, C. (209) 139
Dimaline, R., see Campbell, B.J. (209) 231
Dockray, G.J., see Campbell, B.J. (209) 231
Drapeau, G., see Rollandy, I. (209) 95
Dumont, M. and Lemaire, S.
Interaction of 1,3-di(2-[5-^{3}H]tolyl)guanidine with σ_2 binding sites in rat heart membrane preparations (209) 245
Durieux, C., Ruiz-Gayo, M. and Roques, B.P.
In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCK_B agonist [^{3}H]pBC 264 (209) 185

East, S.J., Batchelor, A.M. and Garthwaite, J.
Selective blockade of N-methyl-D-aspartate receptor function by the nitric oxide donor, nitroprusside (209) 119
Edvinsson, L., see Heilig, M. (209) 27

Eglezos, A., Giuliani, S., Viti, G. and Maggi, C.A.
Direct evidence that capsaicin-induced plasma protein extravasation is mediated through tachykinin NK_1 receptors (209) 277
Emri, Z., see Juhász, G. (209) 131
Erdö, S.L., see Kiss, B. (209) 109
Eurin, J., see Zongazo, M.A. (209) 45

Fekete, I., see Molnár, L. (209) 81
Feldman, J., see Tibiriça, E. (209) 213
Fletcher, P.J., see Kish, S.J. (209) 101
Fredholm, B.B., see Hu, P.-S. (209) 87

Gacel, G., see Calenco-Choukroun, G. (209) 267
Gale, K., see Meloni, R. (209) 113
Garthwaite, J., see East, S.J. (209) 119
Gay, N., see Lepetit, P. (209) 207
Gemma, C., Ghezzi, P. and De Simoni, M.G.
Activation of the hypothalamic serotoninergic system by central interleukin-1 (209) 139
Gertner, S.B., see McLeod, R.L. (209) 141
Ghezzi, P., see Gemma, C. (209) 139
Giuliani, S., see Eglezos, A. (209) 277
Gonon, F., see Tibiriça, E. (209) 213
Grange, E., see Lepetit, P. (209) 207
Gui-Hua, C. and Woolverton, W.L.
Antagonism of quinpirole by (+)-AJ 76: possible involvement of D_3 receptors (209) 285
Guillemain, I., see Rollandy, I. (209) 95

Hammer, Jr., R.P., Seatriz, J.V. and Ricalde, A.R.
Regional dependence of morphine-induced μ-opiate receptor down-regulation in perinatal rat brain (209) 253
Hara, H., Onodera, H., Kawagoe, J.-i. and Kogure, K.
Failure of basic fibroblast growth factor to prevent postischemic neuronal damage in the rat (209) 195
Harhammer, R., Schäfer, U., Henklein, P., Ott, T. and Repke, H.
CCK-8-related C-terminal tetrapeptides: affinities for central CCK_B and peripheral CCK_A receptors (209) 263
Hashimoto, M., Hashimoto, T. and Kuriyama, K.
Protective effect of WEB 1881 FU on AF64A (ethylcholine aziridinium ion)-induced impairment of hippocampal cholinergic neurons and learning acquisition (209) 9
Hashimoto, T., see Hashimoto, M. (209) 9
Hegedüs, K., see Molnár, L. (209) 81
Heilig, M., Edvinsson, L. and Wahlestedt, C.
Effects of intracerebroventricular D-myo-inositol-1,2,6-trisphosphate (PP56), a proposed neuropeptide Y (NPY) antagonist, on locomotor activity, food intake, central effects of NPY and NPY-receptor binding (209) 27
Henklein, P., see Harhammer, R. (209) 263
Hey, J.A., see McLeod, R.L. (209) 141
Hjorth, S. and Tao, R.
The putative $5\text{-}HT_{1D}$ receptor agonist CP-93,129 suppresses rat hippocampal 5-HT release in vivo: comparison with RU 24969 (209) 249
Hofman, G., see Van Oosterhout, A.J.M. (209) 237

Horiuchi, A., see Iwatsuki, K. (209) 63
Howbert, J.J., see Rasmussen, K. (209) 135
Hu, P.-S., Benishin, C. and Fredholm, B.B.
Comparison of the effects of four dendrotoxin peptides, 4-aminopyridine and tetraethylammonium on the electrically evoked [^{3}H]noradrenaline release from rat hippocampus (209) 87
Hughes, J., see Campbell, B.J. (209) 231

Imhoff, V., see Rollandy, I. (209) 95
Inukai, T., see Shimomura, Y. (209) 15
Iwatsuki, K., Horiuchi, A., Ren, L.-M. and Chiba, S.
Effects of the cyclic nucleotide phosphodiesterase inhibitors, rolipram, 3-isobutyl-1-methylxanthine, amrinone and zaprinast, on pancreatic exocrine secretion in dogs (209) 63

Juhász, G., Kékesi, K.A., Emri, Z., Ujszászi, J., Krogsgaard–Larsen, P. and Schousboe, A.
Sleep promoting effect of a putative glial γ-aminobutyric acid uptake blocker applied in the thalamus of cats (209) 131

Kalbfleisch, J., see Kostrzewa, R.M. (209) 157
Kauffman, G., see Saperas, E. (209) 1
Kawagoe, J.-i., see Hara, H. (209) 195
Kékesi, K.A., see Juhász, G. (209) 131
Kelley, K.W., see Bluthé, R.-M. (209) 281
Kikuchi de Beltrán, K., see Koshikawa, N. (209) 75
Kim, Y.S., see Molenaar, P. (209) 257
Kish, S.J., Wilson, J.M. and Fletcher, P.J.
The polyamine synthesis inhibitor α-difluoromethylornithine is neuroprotective against N-methyl-D-aspartate-induced brain damage in vivo (209) 101
Kiss, B., Cai, N.-s. and Erdő, S.L.
Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies (209) 109
Klee, A., Schmid-Schönbein, G.W. and Seiffge, D.
Effects of platelet activating factor on rat platelets in vivo (209) 223
Kobayashi, I., see Shimomura, Y. (209) 15
Kobayashi, M., see Koshikawa, N. (209) 75
Kobayashi, S., see Shimomura, Y. (209) 15
Koekkoek-Van den Herik, I., see Van de Heijning, B.J.M. (209) 199
Kogure, K., see Hara, H. (209) 195
Komajda, M., see Zongazo, M.A. (209) 45
Koshikawa, N., Kikuchi de Beltrán, K., Saigusa, T., Kobayashi, M. and Stephenson, J.D.
Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomorphine-induced jaw movements in rats (209) 75
Kostrzewa, R.M., Brus, R. and Kalbfleisch, J.
Ontogenetic homologous sensitization to the antinociceptive action of quinpirole in rats (209) 157
Krogsgaard–Larsen, P., see Juhász, G. (209) 131
Kuriyama, K., see Hashimoto, M. (209) 9
Kuwabara, A., see Shimomura, Y. (209) 15

Lee, K.S., see Arlinghaus, L. (209) 123
Legrand, J.C., see Zongazo, M.A. (209) 45
Le Greves, P., see Andersson, S.E. (209) 175
Lemaire, S., see Dumont, M. (209) 245
Lepetit, P., Touret, M., Grange, E., Gay, N. and Bobillier, P.
Inhibition of methionine incorporation into brain proteins after the systemic administration of p-chlorophenylalanine and L-5-hydroxytryptophan (209) 207

Mabley, J., Wayman, C.P. and Wilson, J.F.
Endogenous γ-aminobutyric acid tonically inhibits release of α-melanocyte-stimulating hormone from rat hypothalamic slices (209) 127
Maggi, C.A., see Eglezos, A. (209) 277
Maigret, C., see Van Wimersma Greidanus, T.B. (209) 57
Maistre, G., see Zongazo, M.A. (209) 45
Masson, F., see Zongazo, M.A. (209) 45
McLeod, R.L., Gertner, S.B. and Hey, J.A.
Modulation of cardiovascular function by central histamine H_3 receptors in conscious guinea pigs (209) 141
Mehdi, S., see Arlinghaus, L. (209) 123
Meloni, R. and Gale, K.
Cocaine-induced turning behavior in rats with 6-hydroxydopamine lesions: effect of transplants of fetal substantia nigra (209) 113
Memo, M., see Pizzi, M. (209) 169
Mermet, C., see Tibiriça, E. (209) 213
Minabe, Y., Ashby, Jr., C.R. and Wang, R.Y.
The effect of acute and chronic LY 277359, a selective 5-HT_3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons (209) 151
Minabe, Y., Ashby, Jr., C.R., Schwartz, J.E. and Wang, R.Y.
The 5-HT_3 receptor antagonists LY 277359 and granisetron potentiate the suppressant action of apomorphine on the basal firing rate of ventral tegmental dopamine cells (209) 143
Molenaar, P., Roberts, S.J., Kim, Y.S., Pak, H.S., Sainz, R.D. and Summers, R.J.
Localization and characterization of two propranolol resistant (−)[^{125}I]cyanopindolol binding sites in rat skeletal muscle (209) 257
Molnár, L., Hegedüs, K. and Fekete, I.
Difference between the cerebrovascular effect of purinergic Co-ATP and that of the cholinesterase inhibitor, physostigmine, in vivo (209) 81
Monassier, L., see Tibiriça, E. (209) 213

Negri, L., Noviello, V. and Angelucci, F.
Behavioural effects of deltorphins in rats (209) 163
Nielsen-Kudsk, J.E. and Thirstrup, S.
Antidiabetic sulfonylureas relax isolated rabbit coronary arteries (209) 273
Nijkamp, F.P., see Van Oosterhout, A.J.M. (209) 237
Noé, E., see Zongazo, M.A. (209) 45
Noviello, V., see Negri, L. (209) 163

Onodera, H., see Hara, H. (209) 195
Ott, T., see Harhammer, R. (209) 263

Pak, H.S., see Molenaar, P. (209) 257
Pizzi, M., Ribola, M., Valerio, A., Memo, M. and Spano, P.F.
Various Ca^{2+} entry blockers prevent glutamate-induced neurotoxicity (209) 169

Rasmussen, K., Stockton, M.E., Czachura, J.F. and Howbert, J.J.
Cholecystokinin (CCK) and schizophrenia: the selective CCK_B antagonist LY262691 decreases midbrain dopamine unit activity (209) 135
Regoli, D., see Rollandy, I. (209) 95
Ren, L.-M., see Iwatsuki, K. (209) 63
Repke, H., see Harhammer, R. (209) 263
Ribola, M., see Pizzi, M. (209) 169
Ricalde, A.R., see Hammer, Jr., R.P. (209) 253
Roberts, S.J., see Molenaar, P. (209) 257

Røed, A.
Separate sites for the dantrolene-induced inhibition of contracture of the rat diaphragm preparation due to depolarization or to caffeine (209) 33
Rollandy, I., Guillemain, I., Imhoff, V., Drapeau, G., Regoli, D. and Rossignol, B.
Involvement of NK_1 receptors and importance of the N-terminal sequence of substance P in the stimulation of protein secretion in rat parotid glands (209) 95
Roques, B.P., see Calenco-Choukroun, G. (209) 267
Roques, B.P., see Durieux, C. (209) 185
Rossignol, B., see Rollandy, I. (209) 95
Ruiz-Gayo, M., see Durieux, C. (209) 185

Saigusa, T., see Koshikawa, N. (209) 75
Sainz, R.D., see Molenaar, P. (209) 257
Sako, K., Tsuchiya, M., Yonemasu, Y. and Asano, T.
HA1077, a novel calcium antagonistic antivasospasm drug, increases both cerebral blood flow and glucose metabolism in conscious rats (209) 39
Salinas, P. and Barrigón, S.
Protective effects of dazmegrel on the PAF potential of ouabain-induced cardiac arrhythmias (209) 105
Saperas, E., Kauffman, G. and Taché, Y.
Role of central prostaglandin E_2 in the regulation of gastric acid secretion in the rat (209) 1
Sato, N., see Shimomura, Y. (209) 15
Schäfer, U., see Harhammer, R. (209) 263
Schmid-Schönbein, G.W., see Klee, A. (209) 223
Schousboe, A., see Juhász, G. (209) 131
Schwartz, J.E., see Minabe, Y. (209) 143
Seatriz, J.V., see Hammer, Jr., R.P. (209) 253
Seiffge, D., see Klee, A. (209) 223
Shikada, K.-i., Yamamoto, A. and Tanaka, S.
NIP-121 and cromakalim, potassium channel openers, preferentially suppress prostanoid-induced contraction of the guinea-pig isolated trachea (209) 69
Shimizu, H., see Shimomura, Y. (209) 15
Shimomura, Y., Inukai, T., Kuwabara, A., Shimizu, H., Sato, N., Uehara, Y., Kobayashi, I. and Kobayashi, S.
Enhanced sensitivity to anorexia and consumption of drinking water induced by interleukin-1β in obese yellow mice (209) 15
Spano, P.F., see Pizzi, M. (209) 169
Stephenson, J.D., see Koshikawa, N. (209) 75
Stockton, M.E., see Rasmussen, K. (209) 135
Strahlendorf, H.K., see Darrow, E. (209) 19
Strahlendorf, J.C., see Darrow, E. (209) 19
Summers, R.J., see Molenaar, P. (209) 257

Taché, Y., see Saperas, E. (209) 1
Tanaka, S., see Shikada, K.-i. (209) 69
Tao, R., see Hjorth, S. (209) 249
Thirstrup, S., see Nielsen-Kudsk, J.E. (209) 273
Tibiriça, E., Feldman, J., Mermet, C., Monassier, L., Gonon, F. and Bousquet, P.
Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors (209) 213
Touret, M., see Lepetit, P. (209) 207
Tsuchiya, M., see Sako, K. (209) 39

Uehara, Y., see Shimomura, Y. (209) 15
Ujszászi, J., see Juhász, G. (209) 131

Valerio, A., see Pizzi, M. (209) 169
Van de Heijning, B.J.M., Koekkoek-Van den Herik, I. and Van Wimersma Greidanus, T.B.
The opioid receptor subtypes μ and κ, but not δ, are involved in the control of the vasopressin and oxytocin release in the rat (209) 199
Van Oosterhout, A.J.M., Hofman, G., Woutersen-Van Nijnanten, F.M.A. and Nijkamp, F.P.
5-HT_1-like receptors mediate potentiation of cholinergic nerve-mediated contraction of isolated mouse trachea (209) 237
Van Wimersma Greidanus, T.B. and Maigret, C.
Neuromedin-induced excessive grooming/scratching behavior is suppressed by naloxone, neurotensin and a dopamine D_1 receptor antagonist (209) 57
Van Wimersma Greidanus, T.B., see Van de Heijning, B.J.M. (209) 199
Viti, G., see Eglezos, A. (209) 277

Wahlestedt, C., see Heilig, M. (209) 27
Wang, R.Y., see Minabe, Y. (209) 143
Wang, R.Y., see Minabe, Y. (209) 151
Wayman, C.P., see Mabley, J. (209) 127
Wilson, J.F., see Mabley, J. (209) 127
Wilson, J.M., see Kish, S.J. (209) 101
Woolverton, W.L., see Gui-Hua, C. (209) 285
Woutersen-Van Nijnanten, F.M.A., see Van Oosterhout, A.J.M. (209) 237

Yamamoto, A., see Shikada, K.-i. (209) 69
Yonemasu, Y., see Sako, K. (209) 39

Zongazo, M.A., Carayon, A., Masson, F., Maistre, G., Noé, E., Eurin, J., Barthelemy, C., Komajda, M. and Legrand, J.C.
Effects of arginine vasopressin and extracellular osmolarity on atrial natriuretic peptide release by superfused rat atria (209) 45

European Journal of Pharmacology, 209 (1991) 291–298
© 1991 Elsevier Science Publishers B.V. All rights reserved 0014-2999/91/$03.50

Key word index

Acetylcholine
WEB 1881 FU; Hippocampus; AF64A; Memory (Hashimoto, M. (209) 9)

Acetylcholine release
Vinpocetine; Excitatory amino acid receptors; Dopamine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

α_2-Adrenoceptors
Transmitter release: K^+ channels; Aminopyridines; Tetraethylammonium (Hu, P.-S. (209) 87)

β-Adrenoceptors (atypical)
Skeletal muscle; (−)-[^{125}I]cyanopindolol; BRL 37344; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

AF64A
WEB 1881 FU; Hippocampus; Acetylcholine; Memory (Hashimoto, M. (209) 9)

Alprenolol
β-Adrenoceptors (atypical); Skeletal muscle; (−)-[^{125}I]cyanopindolol; BRL 37344; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

Aminopyridines
Transmitter release: K^+ channels; Tetraethylammonium: α_2-Adrenoceptors (Hu, P.-S. (209) 87)

AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid)
Glutamate; Ca^{2+} entry blockers; Neurotoxicity (Pizzi, M. (209) 169)

AMPA binding
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate (Kiss, B. (209) 109)

Amphetamine
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; Nomifensine; GBR 12909 (Meloni, R. (209) 113)

Analgesia
Deltorphins; δ-Opioid receptors; Locomotor activity; Social behaviour; (Rat) (Negri, L. (209) 163)

ANP release
Atrium (rat); Ca^{2+} influence; V_1 receptor antagonists; Osmolarity (Zongazo, M.A. (209) 45)

Antinociception
Quinpirole; Dopamine; Receptor sensitization (Kostrzewa, R.M. (209) 157)

Antipsychotic drugs
Cholecystokinin (CCK); CCK_B receptors; Schizophrenia; Dopamine neurons; LY262691 (Rasmussen, K. (209) 135)

Apomorphine
CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

Appetitive behaviour
Interleukin-1β; Ibuprofen; (Yellow mice) (Shimomura, Y. (209) 15)

ATP
Physostigmine; Cerebral vasodilatation; (Mode of action); (Rabbit) (Molnár, L. (209) 81)

Atrium (rat)
ANP release; Ca^{2+} influence; V_1 receptor antagonists; Osmolarity (Zongazo, M.A. (209) 45)

Autoradiography (quantitative)
p-Chlorophenylalanine; L-5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Brain protein synthesis (Lepetit, P. (209) 207)

Azepexole
Rilmenidine; Clonidine; Voltammetry (in vivo); Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Baclofen
Prostaglandin E_2; Indomethacin; Gastric acid secretion; Vagus (Saperas, E. (209) 1)

Basal ganglia
Dopamine uptake; Striatum; Postural asymmetry; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Benzodiazepines
α-MSH (α-melanocyte-stimulating hormone); GABA (γ-aminobutyric acid); Hypothalamus (Mabley, J. (209) 127)

Binding in vivo
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

Blood-aqueous barrier
CGRP (calcitonin gene-related peptide); Capsaicin; Miosis; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

Blood pressure
Rilmenidine; Azepexole; Clonidine; Voltammetry (in vivo); Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Body weight
Tumor necrosis factor; Interleukin-1; Interleukin-1 receptor antagonists; Social behaviour; (Mouse) (Bluthé, R.-M. (209) 281)

Brain protein synthesis
p-Chlorophenylalanine; L-5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Autoradiography (quantitative) (Lepetit, P. (209) 207)

Brain (rat)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Microdialysis (Hjorth, S. (209) 249)

BRL 37344
β-Adrenoceptors (atypical); Skeletal muscle; (−)-[^{125}I]cyanopindolol; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

Ca^{2+} entry blockers
Glutamate; AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid); Neurotoxicity (Pizzi, M. (209) 169)

Caerulein
CCK-8 (cholecystokinin octapeptide); Lorglumide; Apomorphine; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

Caffeine contracture
Dantrolene; Depolarization contractures; Diaphragm (rat) (Røed, A. (209) 33)

Ca^{2+} influence
Atrium (rat); ANP release; V_1 receptor antagonists; Osmolarity (Zongazo, M.A. (209) 45)

Calpain inhibitor
Neuroprotection; Hypoxia; Hippocampal slice; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Capsaicin
Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Miosis; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

CCK-8 (cholecystokinin octapeptide)
Caerulein; Lorglumide; Apomorphine; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

CCK_B receptors; Tetrapeptides; (Radioligand binding) (Harhammer, R. (209) 263)

CCK receptor agonists
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

CCK receptor antagonists
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor agonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

CCK_B receptors
Cholecystokinin (CCK); Schizophrenia; Dopamine neurons; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

CCK-8 (cholecystokinin octapeptide); Binding in vivo; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

CCK-8 (cholecystokinin octapeptide); Tetrapeptides; (Radioligand binding) (Harhammer, R. (209) 263)

Cerebellum
NMDA receptors; Nitroprusside; Nitric oxide (NO); cGMP (East, S.J. (209) 119)

Cerebral blood flow
Cerebral glucose metabolism; Iodoantipyrine; 2-Deoxyglucose; HA1077 (Sako, K. (209) 39)

Cerebral glucose metabolism
Cerebral blood flow; Iodoantipyrine; 2-Deoxyglucose; HA1077 (Sako, K. (209) 39)

Cerebral ischemia
bFGF (basic fibroblast growth factor); Hippocampus; Vulnerability (selective); (Rat) (Hara, H. (209) 195)

Cerebral vasodilatation
ATP; Physostigmine; (Mode of action); (Rabbit) (Molnár, L. (209) 81)

CGRP (calcitonin gene-related peptide)
Blood-aqueous barrier; Capsaicin; Miosis; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

p-Chlorophenylalanine
L-5-Hydroxytryptophan; 5-HT (5-hydroxytryptamine, serotonin); Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P. (209) 207)

Cholecystokinin (CCK)
CCK_B receptors; Schizophrenia; Dopamine neurons; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

Clonidine
Rilmenidine; Azepexole; Voltammetry (in vivo); Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Coronary aretery
Sulfonylureas; Glibenclamide; Cromakalim; K^+ channels; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

(±)-CP-96,345
Plasma protein extravasation; Neurogenic inflammation; Tachykinin NK_1 receptors (Eglezos, A. (209) 277)

CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one)
5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

Cromakalim
K^+ channel opener; NIP-121; Glibenclamide; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Sulfonylureas; Glibenclamide; K^+ channels; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

(−)-[^{125}I]cyanopindolol
β-Adrenoceptors (atypical); Skeletal muscle; BRL 37344; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

[^{3}H]DAGO binding
Opiates; Development; Hypothalamus (Hammer, Jr., R.P. (209) 253)

DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2)
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Dantrolene
Depolarization contractures; Caffeine contracture; Diaphragm (rat) (Røed, A. (209) 33)

Dazmegrel
PAF (platelet-activating factor, PAF-acether); Lysine-acetylsalicylate; Ouabain-induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 105)

Deltorphins
δ-Opioid receptors; Locomotor activity; Social behaviour; Analgesia; (Rat) (Negri, L. (209) 163)

2-Deoxyglucose
Cerebral blood flow; Cerebral glucose metabolism; Iodoantipyrine; HA1077 (Sako, K. (209) 39)

Depolarization contractures
Dantrolene; Caffeine contracture; Diaphragm (rat) (Røed, A. (209) 33)

Desensitization
PAF-specific; Pulmonary platelet accumulation; (Rat) (Klee, A. (209) 223)

Development
Opiates; [^{3}H]DAGO binding; Hypothalamus (Hammer, Jr., R.P. (209) 253)

Diaphragm (rat)
Dantrolene; Depolarization contractures; Caffeine contracture (Røed, A. (209) 33)

α-Difluoromethylornithine
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

Dopamine
Antinociception; Quinpirole; Receptor sensitization (Kostrzewa, R.M. (209) 157)

Dopamine cells
5-HT_3 receptor antagonists; LY 277359; Granisetron; Ventral tegmental area (Minabe, Y. (209) 143)

Dopamine neurons
Cholecystokinin (CCK); CCK_B receptors; Schizophrenia; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

5-HT_3 receptors; 5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

Dopamine release
Vinpocetine; Excitatory amino acid receptors; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

Dopamine uptake
Striatum; Postural asymmetry; Basal ganglia; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Dorsomedial nucleus accumbens
CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Apomorphine; Jaw movements (Koshikawa, N. (209) 75)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin)
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); U-69,593 (Van de Heijning, B.J.M. (209) 199)

DTG (1,3-di(2-tolyl)guanidine)
σ Receptors; Phencyclidine (PCP); SK&F 10047 (Dumont, M. (209) 245)

Electrical field stimulation
5-HT (5-hydroxytryptamine, serotonin); Trachea; Respiratory airways (Van Oosterhout, A.J.M. (209) 237)

Excitatory amino acid receptors
Vinpocetine; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

Exocrine secretion
Pancreas (dog); Phosphodiesterase inhibitors; Rolipram (Iwatsuki, K. (209) 63)

bFGF (basic fibroblast growth factor)
Cerebral ischemia; Hippocampus; Vulnerability (selective); (Rat) (Hara, H. (209) 195)

Food intake
Omeprazole; Gastrin; (Chicken) (Campbell, B.J. (209) 231)

GABA (γ-aminobutyric acid)
α-MSH (α-melanocyte-stimulating hormone); Benzodiazepines; Hypothalamus (Mabley, J. (209) 127)

Glial uptake; Thalamus; Sleep; (Cat) (Juhász, G. (209) 131)

Gastric acid secretion
Prostaglandin E_2; Indomethacin; Vagus; Baclofen (Saperas, E. (209) 1)

Gastrin
Omeprazole; Food intake; (Chicken) (Campbell, B.J. (209) 231)

GBR 12909
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; Nomifensine; Amphetamine (Meloni, R. (209) 113)

Glial uptake
GABA (γ-aminobutyric acid); Thalamus; Sleep; (Cat) (Juhász, G. (209) 131)

Glibenclamide
K^+ channel opener; NIP-121; Cromakalim; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Sulfonylureas; Cromakalim; K^+ channels; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

Glutamate
AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid); Ca^{2+} entry blockers; Neurotoxicity (Pizzi, M. (209) 169)

cGMP
Cerebellum; NMDA receptors; Nitroprusside; Nitric oxide (NO) (East, S.J. (209) 119)

Granisetron
5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area; Dopamine cells (Minabe, Y. (209) 143)

Grooming/scratching behaviour
Neuromedin B; Neuromedin C (Van Wimersma Greidanus, T.B. (209) 57)

HA1077
Cerebral blood flow; Cerebral glucose metabolism; Iodoantipyrine; 2-Deoxyglucose (Sako, K. (209) 39)

Hippocampal slice
Neuroprotection; Calpain inhibitor; Hypoxia; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Hippocampus
WEB 1881 FU; Acetylcholine; AF64A; Memory (Hashimoto, M. (209) 9)

bFGF (basic fibroblast growth factor); Cerebral ischemia; Vulnerability (selective); (Rat) (Hara, H. (209) 195)

5-HT (5-hydroxytryptamine, serotonin)
Purkinje neurons; Microiontophoresis; 5-HT_{1A} receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

p-Chlorophenylalanine; L-5-Hydroxytryptophan; Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P. (209) 207)

Electrical field stimulation; Trachea; Respiratory airways (Van Oosterhout, A.J.M. (209) 237)

β-Adrenoceptors (atypical); Skeletal muscle; (−)-[^{125}I]cyanopindolol; BRL 37344; Alprenolol (Molenaar, P. (209) 257)

5-HT_{1B} receptor agonists
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

5-HT_3 receptor antagonists
LY 277359; Granisetron; Ventral tegmental area; Dopamine cells (Minabe, Y. (209) 143)

Dopamine neurons; 5-HT_3 receptors; LY 277359; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

5-HT_{1A} receptors
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

5-HT_3 receptors
Dopamine neurons; 5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

5-HT release (in vivo)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

6-Hydroxydopamine (6-OHDA)
μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

L-5-Hydroxytryptophan
p-Chlorophenylalanine; 5-HT (5-hydroxytryptamine, serotonin); Brain protein synthesis; Autoradiography (quantitative) (Lepetit, P. (209) 207)

Hypothalamus
α-MSH (α-melanocyte-stimulating hormone); GABA (γ-aminobutyric acid); Benzodiazepines (Mabley, J. (209) 127)

Opiates; [^{3}H]DAGO binding; Development (Hammer, Jr., R.P. (209) 253)

Hypoxia
Neuroprotection; Calpain inhibitor; Hippocampal slice; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Ibuprofen
Interleukin-1β; Appetitive behaviour; (Yellow mice) (Shimomura, Y. (209) 15)

Imidazoline-preferring receptors
Rilmenidine; Azepexole; Clonidine; Voltammetry (in vivo); Blood pressure (Tibiriça, E. (209) 213)

Indomethacin
Prostaglandin E_2; Gastric acid secretion; Vagus; Baclofen (Saperas, E. (209) 1)

Interleukin-1
Tumor necrosis factor; Interleukin-1 receptor antagonists; Social behaviour; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

Interleukin-1β
Appetitive behaviour; Ibuprofen; (Yellow mice) (Shimomura, Y. (209) 15)

Interleukin-1 receptor antagonists
Tumor necrosis factor; Interleukin-1; Social behaviour; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

Iodoantipyrine
Cerebral blood flow; Cerebral glucose metabolism; 2-Deoxyglucose; HA1077 (Sako, K. (209) 39)

IP_3
Neuropeptide Y (NPY); Locomotion; (Feeding); (Receptors) (Heilig, M. (209) 27)

Jaw movements
CCK-8 (cholecystokinin octapeptide); Caerulein; Lorglumide; Apomorphine; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

Kainate
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; AMPA binding (Kiss, B. (209) 109)

K^+ channel opener
NIP-121; Cromakalim; Glibenclamide; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

K^+ channels
Sulfonylureas; Glibenclamide; Cromakalim; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

Kelatorphan
μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

Locomotion
Neuropeptide Y (NPY); IP_3; (Feeding); (Receptors) (Heilig, M. (209) 27)

Locomotor activity
Deltorphins; δ-Opioid receptors; Social behaviour; Analgesia; (Rat) (Negri, L. (209) 163)

μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens (Calenco-Choukroun, G. (209) 267)

Lorglumide
CCK-8 (cholecystokinin octapeptide); Caerulein; Apomorphine; Jaw movements; Dorsomedial nucleus accumbens (Koshikawa, N. (209) 75)

LY262691
Cholecystokinin (CCK); CCK_B receptors; Schizophrenia; Dopamine neurons; Antipsychotic drugs (Rasmussen, K. (209) 135)

LY 277359
5-HT_3 receptor antagonists; Granisetron; Ventral tegmental area; Dopamine cells (Minabe, Y. (209) 143)

Dopamine neurons; 5-HT_3 receptors; 5-HT_3 receptor antagonists; Ventral tegmental area; Substantia nigra pars compacta (Minabe, Y. (209) 151)

Lysine-acetylsalicylate
Dazmegrel; PAF (platelet-activating factor, PAF-acether); Ouabain-induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 105)

Memory
WEB 1881 FU; Hippocampus; Acetylcholine; AF64A (Hashimoto, M. (209) 9)

Methiothepin
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

Mg^{2+}
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Microdialysis
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole); Methiothepin; 5-HT release (in vivo); Brain (rat) (Hjorth, S. (209) 249)

Microiontophoresis
Purkinje neurons; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Miosis
Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Capsaicin; Ruthenium red; Substance P (Andersson, S.E. (209) 175)

α-MSH (α-melanocyte-stimulating hormone)
GABA (γ-aminobutyric acid); Benzodiazepines; Hypothalamus (Mabley, J. (209) 127)

Nalosone
Vasopressin; Oxytocin; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Naltrindole
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Neurogenic inflammation
(±)-CP-96,345; Plasma protein extravasation; Tachykinin NK_1 receptors (Eglezos, A. (209) 277)

Neuromedin B
Neuromedin C; Grooming/scratching behaviour (Van Wimersma Greidanus, T.B. (209) 57)

Neuromedin C
Neuromedin B; Grooming/scratching behaviour (Van Wimersma Greidanus, T.B. (209) 57)

Neuropeptide Y (NPY)
IP_3; Locomotion; (Feeding); (Receptors) (Heilig, M. (209) 27)

Neuroprotection
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; α-Difluoromethylornithine; Ornithine decarboxylase (Kish, S.J. (209) 101)

Calpain inhibitor; Hypoxia; Hippocampal slice; Proteolysis; (Rat) (Arlinghaus, L. (209) 123)

Neurotoxicity
Polyamine; NMDA (N-methyl-D-aspartate); α-Difluoromethylornithine; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

Glutamate; AMPA (2-amino-3-(3-hydroxy-5-methylisoxazolyl)-propionic acid); Ca^{2+} entry blockers (Pizzi, M. (209) 169)

NIP-121
K^+ channel opener; Cromakalim; Glibenclamide; Prostaglandin; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Nitric oxide (NO)
Cerebellum; NMDA receptors; Nitroprusside; cGMP (East, S.J. (209) 119)

Nitroprusside
Cerebellum; NMDA receptors; Nitric oxide (NO); cGMP (East, S.J. (209) 119)

NMDA (N-methyl-D-aspartate)
Polyamine; Neurotoxicity; α-Difluoromethylornithine; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

NMDA receptors
Cerebellum; Nitroprusside; Nitric oxide (NO); cGMP (East, S.J. (209) 119)

Nomifensine
Dopamine uptake; Striatum; Postural asymmetry; Basal ganglia; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Norbinaltorphimine (norBNI)
Vasopressin; Oxytocin; Naloxone; Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

N-terminal part
Tachykinins; Protein secretion; Substance P; Parotid glands (Rollandy, I. (209) 95)

Nucleus accumbens
μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Locomotor activity (Calenco-Choukroun, G. (209) 267)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin)
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1A}$ receptors; Mg^{2+}; TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Omeprazole
Gastrin; Food intake; (Chicken) (Campbell, B.J. (209) 231)

Opiates
[^{3}H]DAGO binding; Development; Hypothalamus (Hammer, Jr., R.P. (209) 253)

δ-Opioid receptor agonists (selective)
μ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

μ-Opioid receptor agonists (selective)
δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Ventral tegmental area; Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

δ-Opioid receptors
Deltorphins; Locomotor activity; Social behaviour; Analgesia; (Rat) (Negri, L. (209) 163)

Ornithine decarboxylase
Polyamine; NMDA (N-methyl-D-aspartate); Neurotoxicity; α-Difluoromethylornithine; Neuroprotection (Kish, S.J. (209) 101)

Osmolarity
Atrium (rat); ANP release; Ca^{2+} influence; V_1 receptor antagonists (Zongazo, M.A. (209) 45)

Ouabain-induced arrhythmia
Dazmegrel; PAF (platelet-activating factor, PAF-acether); Lysine-acetylsalicylate; (Guinea-pig) (Salinas, P. (209) 105)

Oxytocin
Vasopressin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

PAF (platelet-activating factor, PAF-acether)
Dazmegrel; Lysine-acetylsalicylate; Ouabain-induced arrhythmia; (Guinea-pig) (Salinas, P. (209) 105)

PAF-specific
Pulmonary platelet accumulation; Desensitization; (Rat) (Klee, A. (209) 223)

Pancreas (dog)
Exocrine secretion; Phosphodiesterase inhibitors; Rolipram (Iwatsuki, K. (209) 63)

Parotid glands
Tachykinins; Protein secretion; Substance P; N-terminal part (Rollandy, I. (209) 95)

[^{3}H]pBC 264
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; Peptidase inhibitors; CCK receptor agonists; CCK receptor antagonists; (Mouse) (Durieux, C. (209) 185)

Peptidase inhibitors
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; Binding in vivo; CCK receptor agonists; CCK receptor antagonists; [^{3}H]pBC 264; (Mouse) (Durieux, C. (209) 185)

Phencyclidine (PCP)
σ Receptors; DTG (1,3-di(2-tolyl)guanidine); SK&F 10047 (Dumont, M. (209) 245)

Phosphodiesterase inhibitors
Pancreas (dog); Exocrine secretion; Rolipram (Iwatsuki, K. (209) 63)

Physostigmine
ATP; Cerebral vasodilatation; (Mode of action); (Rabbit) (Molnár, L. (209) 81)

Plasma protein extravasation
(±)-CP-96,345; Neurogenic inflammation; Tachykinin NK_1 receptors (Eglezos, A. (209) 277)

Polyamine
NMDA (N-methyl-D-aspartate); Neurotoxicity; α-Difluoromethylornithine; Ornithine decarboxylase; Neuroprotection (Kish, S.J. (209) 101)

Postural asymmetry
Dopamine uptake; Striatum; Basal ganglia; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Prostaglandin
K^+ channel opener; NIP-121; Cromakalim; Glibenclamide; Trachea (isolated, guinea-pig) (Shikada, K.-i. (209) 69)

Prostaglandin E_2
Indomethacin; Gastric acid secretion; Vagus; Baclofen (Saperas, E. (209) 1)

Protein secretion
Tachykinins; Substance P; N-terminal part; Parotid glands (Rollandy, I. (209) 95)

Proteolysis
Neuroprotection; Calpain inhibitor; Hypoxia; Hippocampal slice; (Rat) (Arlinghaus, L. (209) 123)

Pulmonary platelet accumulation
PAF-specific; Desensitization; (Rat) (Klee, A. (209) 223)

Purkinje neurons
Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); TFMPP (trifluoromethylphenylpiperazine) (Darrow, E. (209) 19)

Quinpirole
Antinociception; Dopamine; Receptor sensitization (Kostrzewa, R.M. (209) 157)

Quisqualate
Vinpocetine; Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Kainate; AMPA binding (Kiss, B. (209) 109)

σ Receptors
DTG (1,3-di(2-tolyl)guanidine); Phencyclidine (PCP); SK&F 10047 (Dumont, M. (209) 245)

Receptor sensitization
Antinociception; Quinpirole; Dopamine (Kostrzewa, R.M. (209) 157)

Respiratory airways
5-HT (5-hydroxytryptamine, serotonin); Electrical field stimulation; Trachea (Van Oosterhout, A.J.M. (209) 237)

Rilmenidine
Azepexole; Clonidine; Voltammetry (in vivo); Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

Rolipram
Pancreas (dog); Exocrine secretion; Phosphodiesterase inhibitors (Iwatsuki, K. (209) 63)

RU 24969 (5-methoxy-3-(1,2,5,6-tetrahydropyridyl)indole)
CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one); 5-HT_{1B} receptor agonists; Methiothepin; 5-HT release (in vivo); Microdialysis; Brain (rat) (Hjorth, S. (209) 249)

Ruthenium red
Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Capsaicin; Miosis; Substance P (Andersson, S.E. (209) 175)

Schizophrenia
Cholecystokinin (CCK); CCK_B receptors; Dopamine neurons; LY262691; Antipsychotic drugs (Rasmussen, K. (209) 135)

Skeletal muscle
β-Adrenoceptors (atypical); (−)-[^{125}I]cyanopindolol; BRL 37344; Alprenolol; 5-HT (5-hydroxytryptamine, serotonin) (Molenaar, P. (209) 257)

SK&F 10047
σ Receptors; DTG (1,3-di(2-tolyl)guanidine); Phencyclidine (PCP) (Dumont, M. (209) 245)

Sleep
GABA (γ-aminobutyric acid); Glial uptake; Thalamus; (Cat) (Juhász, G. (209) 131)

Smooth muscle
Sulfonylureas; Glibenclamide; Cromakalim; K^+ channels; Coronary aretery (Nielsen-Kudsk, J.E. (209) 273)

Social behaviour
Deltorphins; δ-Opioid receptors; Locomotor activity; Analgesia; (Rat) (Negri, L. (209) 163)

Tumor necrosis factor; Interleukin-1; Interleukin-1 receptor antagonists; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

Striatum
Dopamine uptake; Postural asymmetry; Basal ganglia; Nomifensine; GBR 12909; Amphetamine (Meloni, R. (209) 113)

Substance P
Tachykinins; Protein secretion; N-terminal part; Parotid glands (Rollandy, I. (209) 95)

Blood-aqueous barrier; CGRP (calcitonin gene-related peptide); Capsaicin; Miosis; Ruthenium red (Andersson, S.E. (209) 175)

Substantia nigra pars compacta
Dopamine neurons; 5-HT_3 receptors; 5-HT_3 receptor antagonists; LY 277359; Ventral tegmental area (Minabe, Y. (209) 151)

Sulfonylureas
Glibenclamide; Cromakalim; K^+ channels; Coronary aretery; Smooth muscle (Nielsen-Kudsk, J.E. (209) 273)

Tachykinin NK_1 receptors
(±)-CP-96,345; Plasma protein extravasation; Neurogenic inflammation (Eglezos, A. (209) 277)

Tachykinins
Protein secretion; Substance P; N-terminal part; Parotid glands (Rollandy, I. (209) 95)

Tetraethylammonium
Transmitter release: K^+ channels; Aminopyridines; α_2-Adrenoceptors (Hu, P.-S. (209) 87)

Tetrapeptides
CCK-8 (cholecystokinin octapeptide); CCK_B receptors; (Radioligand binding) (Harhammer, R. (209) 263)

TFMPP (trifluoromethylphenylpiperazine)
Purkinje neurons; Microiontophoresis; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Mg^{2+}; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (Darrow, E. (209) 19)

Thalamus
GABA (γ-aminobutyric acid); Glial uptake; Sleep; (Cat) (Juhász, G. (209) 131)

Trachea
5-HT (5-hydroxytryptamine, serotonin); Electrical field stimulation; Respiratory airways (Van Oosterhout, A.J.M. (209) 237)

Trachea (isolated, guinea-pig)
K^+ channel opener; NIP-121; Cromakalim; Glibenclamide; Prostaglandin (Shikada, K.-i. (209) 69)

Transmitter release: K^+ channels
Aminopyridines; Tetraethylammonium; α_2-Adrenoceptors (Hu, P.-S. (209) 87)

Tumor necrosis factor
Interleukin-1; Interleukin-1 receptor antagonists; Social behaviour; Body weight; (Mouse) (Bluthé, R.-M. (209) 281)

U-69,593
Vasopressin; Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Van de Heijning, B.J.M. (209) 199)

Vagus
Prostaglandin E_2; Indomethacin; Gastric acid secretion; Baclofen (Saperas, E. (209) 1)

Vasopressin
Oxytocin; Naloxone; Norbinaltorphimine (norBNI); Naltrindole; DALDA (H-Tyr-D-Arg-Phe-Lys-NH_2); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U-69,593 (Van de Heijning, B.J.M. (209) 199)

Ventral tegmental area
5-HT_3 receptor antagonists; LY 277359; Granisetron; Dopamine cells (Minabe, Y. (209) 143)

Dopamine neurons; 5-HT_3 receptors; 5-HT_3 receptor antagonists; LY 277359; Substantia nigra pars compacta (Minabe, Y. (209) 151)

μ-Opioid receptor agonists (selective); δ-Opioid receptor agonists (selective); Kelatorphan; 6-Hydroxydopamine (6-OHDA); Nucleus accumbens; Locomotor activity (Calenco-Choukroun, G. (209) 267)

Vinpocetine
Excitatory amino acid receptors; Dopamine release; Acetylcholine release; NMDA (N-methyl-D-aspartate; Quisqualate; Kainate; AMPA binding (Kiss, B. (209) 109)

Voltammetry (in vivo)
Rilmenidine; Azepexole; Clonidine; Blood pressure; Imidazoline-preferring receptors (Tibiriça, E. (209) 213)

V_1 receptor antagonists
Atrium (rat); ANP release; Ca^{2+} influence; Osmolarity (Zongazo, M.A. (209) 45)

Vulnerability (selective)
bFGF (basic fibroblast growth factor); Cerebral ischemia; Hippocampus; (Rat) (Hara, H. (209) 195)

WEB 1881 FU
Hippocampus; Acetylcholine; AF64A; Memory (Hashimoto, M. (209) 9)